Drug Profile
Alpha 1-Antitrypsin - Octapharma
Alternative Names: OctaAlpha1Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator Octapharma
- Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
- Mechanism of Action Serine endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alpha 1-antitrypsin deficiency
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Alpha-1-antitrypsin-deficiency in Switzerland (IV, Infusion)
- 10 Apr 2018 Octapharma withdraws a phase II trial for alpha1-antitrypsin deficiency prior to enrolment as the IND has been closed (NCT03385395)
- 28 Dec 2017 Octapharma plans a phase II trial for alpha1-antitrypsin deficiency in July 2018 (NCT03385395)